Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSpronck, Bart
dc.contributor.authorAvolio, Alberto
dc.contributor.authorBoutouyrie, Pierre
dc.contributor.authorJeroncic, Ana
dc.contributor.authorTerentes-Printzios, Dimitrios
dc.contributor.authorGuala, Andrea
dc.date.accessioned2024-02-05T08:12:25Z
dc.date.available2024-02-05T08:12:25Z
dc.date.issued2024-01
dc.identifier.citationSpronck B, Terentes-Printzios D, Avolio AP, Boutouyrie P, Guala A, Jerončić A, et al. 2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices. Hypertension. 2024 Jan;81(1):183–92.
dc.identifier.issn0194-911X
dc.identifier.urihttps://hdl.handle.net/11351/10973
dc.descriptionCardiovascular diseases; Pulse wave analysis; Vascular stiffness
dc.description.abstractBACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations. METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices. RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice. CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.
dc.language.isoeng
dc.publisherWolters Kluwer Health
dc.relation.ispartofseriesHypertension;81(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectHipotensió arterial - Diagnòstic
dc.subject.meshHypertension
dc.subject.meshPulse Wave Analysis
dc.subject.meshVascular Stiffness
dc.title2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1161/HYPERTENSIONAHA.123.21618
dc.subject.decshipertensión
dc.subject.decsanálisis de la onda del pulso
dc.subject.decsrigidez vascular
dc.relation.publishversionhttps://doi.org/10.1161/HYPERTENSIONAHA.123.21618
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Spronck B] Department of Biomedical Engineering, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Netherlands. Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia. [Terentes-Printzios D] 1st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, Greece. [Avolio AP] Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia. [Boutouyrie P] Hôpital Européen Georges Pompidou, Paris, France. [Guala A] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación en Red en Enfermedades Cardiovasculares (CIBER-CV), Instituto de Salud Carlos III, Madrid, Spain. [Jerončić A] Laboratory of Vascular Aging and Cardiovascular Prevention, Department of Research in Biomedicine and Health, University of Split School of Medicine, Croatia
dc.identifier.pmid37975229
dc.identifier.wos001127998200021
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record